Xiidra costs roughly $730 for a 30-day supply without insurance, making it one of the priciest prescription eye drops on the market. Several factors drive that price: it’s the only drug of its kind, it’s protected by patents until 2033, its manufacturer paid billions to acquire it, and the molecule itself is genuinely difficult to produce.
It’s the Only Drug in Its Class
Xiidra (lifitegrast) works differently from every other prescription dry eye treatment available. It blocks a specific interaction between two proteins on the surface of immune cells, preventing the chain reaction that leads to inflammation on the eye. Other prescription dry eye drops, like Restasis and Cequa, suppress the immune system through a completely different pathway. That makes Xiidra a first-in-class drug with no direct competitors sharing its mechanism, which gives its manufacturer significant pricing power. If your eyes don’t respond to the alternatives, Xiidra is the only option in this lane.
Patent Protection Until 2033
The last qualifying patent on lifitegrast doesn’t expire until July 2033. Until then, no generic version can legally enter the U.S. market. Four companies have filed applications with the FDA to eventually produce generic versions, and at least one has been granted eligibility for a 180-day exclusivity window once those patents clear. But a decade of patent protection still remains, and that timeline keeps Xiidra free from the price competition that generics typically bring. For context, when generics do arrive for specialty eye drops, prices often fall by 50% or more within the first year or two.
A $1.75 Billion Acquisition Price Tag
Bausch + Lomb purchased Xiidra and related ophthalmology assets from Novartis for $1.75 billion upfront, with milestone payments that could push the total to $2.5 billion. That’s a massive investment the company needs to recoup through sales revenue. Before that deal, Novartis had acquired Xiidra from Shire for a similarly large sum. Each time the drug changes hands at a premium, the new owner has even more financial incentive to maintain or raise its price to justify the purchase.
The Molecule Is Hard to Make
Lifitegrast isn’t a simple compound to manufacture. The production process involves a key chemical step where the molecule can “flip” into a mirror-image version of itself, a problem called racemization. That unwanted mirror image needs to be controlled to extremely low levels (below 0.15% of the daily dose), but the reaction conditions that complete the synthesis also promote this unwanted flip at rates up to 10%. Manufacturers have to thread the needle between temperatures that are high enough to complete the reaction but low enough to limit this side product.
Beyond that, intermediate compounds in the process form sticky, gummy solids that are difficult to remove from equipment and require multiple purification steps, reducing the overall yield. The synthesis also requires expensive palladium catalysts and multiple rounds of adding and removing protective chemical groups. Impurities called dimers form during production and are difficult to purify out to the standards required by international pharmaceutical guidelines. All of this adds up to higher manufacturing costs compared to simpler drug molecules.
How It Compares to Other Dry Eye Drops
Without insurance, Xiidra runs about $731 for a 30-day supply (60 single-use vials). Restasis, the older cyclosporine-based option, costs roughly $639 for a comparable supply. So Xiidra carries a premium of about $90 per month over its closest brand-name competitor. Generic cyclosporine eye drops are now available and cost substantially less than either brand, which makes the gap between Xiidra and the cheapest effective prescription option even wider.
Insurance Hurdles Add Friction
Most insurance plans require prior authorization before they’ll cover Xiidra. A typical set of criteria, like the one used by the North Carolina State Health Plan, requires that the drug is being prescribed for dry eye disease and that you’ve already tried and failed an artificial tears product, or that you can’t tolerate one, or that you have a medical reason not to use one. Some plans go further and require you to try a cheaper prescription drop like generic cyclosporine before they’ll approve Xiidra. These step-therapy requirements don’t lower the drug’s price, but they do control who gets access to it, which reduces the insurer’s overall spending.
Ways to Lower Your Out-of-Pocket Cost
Bausch + Lomb offers a Xiidra Savings Card for patients with commercial insurance (not Medicare, Medicaid, or other government plans). With the card, you may pay $0 on your first 90-day prescription and as little as $0 on each refill. Patients with high-deductible plans or significant coinsurance may still owe something, but the savings card can dramatically reduce costs compared to the sticker price.
If you’re on Medicare or uninsured, the savings card won’t apply. In that case, it’s worth asking your ophthalmologist about manufacturer patient assistance programs, which sometimes cover the full cost for qualifying low-income patients. You can also ask whether a generic cyclosporine drop might work for your situation, since that remains the most affordable prescription route for dry eye treatment right now.